Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

2 clinical studies listed.

Filters:

LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\)

Tundra lists 2 LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06503367

Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy

The goal of this observational study is to understand how young children with LAMA2-related dystrophy move and change over time. We will also learn about how this condition impacts other body systems. Participants will undergo: * Neuromuscular assessments * Blood collections * Swallowing and breathing assessments * Questionnaires

Gender: All

Ages: Any - 5 Years

Updated: 2026-04-08

12 states

LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\)
RECRUITING

NCT07125040

Characterization of the Natural History of LAMA2-RD and Identification of Novel Disease Biomarkers

The goal of this observational study is to learn about the natural history and multi-organ involvement of Laminin-Alpha-2-Related Dystrophy (LAMA2-RD) in pediatric and adult patients. The main questions it aims to answer are: * What is the prevalence and nature of cardiac involvement, and how do this relate to age and muscular phenotype? * What is the prevalence of peripheral neuropathy, and how do this relate to age and muscular phenotype? * What is the extent of respiratory, nutritional, skeletal, and cognitive/brain involvement, particularly in adults with more severe vs less severe phenotypes? * How does quality of life and transition to adulthood occur in individuals with LAMA2-RD? * Which nomenclature best reflects differences in disease severity and may support future clinical trial design? Study participants will: * Undergo retrospective and prospective clinical assessments every 12 months for 2 years across multiple centers. * A subset of adult participants (n=20) will receive cardiac MRI with contrast enhancement. * Provide biological samples during routine blood testing for future research.

Gender: All

Updated: 2025-08-15

LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)
LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\)
Merosin Deficient CMD (Full or Partial)
+1